Registered title, quoted from ClinicalTrials.gov
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 15 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 16
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteAffiliated Zhongshan Hospital of Dalian University大连大学附属中山医院ZhongshanHospital page
- Study siteFirst Affiliated Hospital of Dalian Medical University大连医科大学附属第一医院DalianHospital page
- Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
- Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
- Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
- Study siteSecond Hospital of Shanxi Medical University山西医科大学第二医院TaiyuanHospital page
- Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteShanxi Cardiovascular Hospital山西省心血管医院TaiyuanHospital page
- Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07725484, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Participation in another investigational drug trial within 4 weeks prior to enrollment or ongoing receipt of any investigational treatment other than the study medication;
Exclusion criterion 5
Pregnant or breastfeeding women;
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07725484, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
Participants must meet all of the following criteria:
- Aged ≥18 years and <75 years;
- A history of chronic heart failure for more than 3 months or clinically documented symptoms of heart failure persisting for more than 3 months;
- Left ventricular ejection fraction (LVEF) <50% as assessed by echocardiography;
- A history of acute myocardial infarction (AMI) more than 3 months prior to enrollment;
- New York Heart Association (NYHA) functional class II-IV;
- Receipt of guideline-directed medical therapy (GDMT) for at least 2 weeks;
- Willingness to participate in the study, with the ability to understand and provide written informed consent.
Exclusion Criteria
Participants meeting any of the following criteria will be excluded:
- Previous cardiac resynchronization therapy (CRT);
- Severe hepatic dysfunction, defined as serum transaminase levels exceeding 3 times the upper limit of normal (ULN), or severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²;
- Uncontrolled malignant arrhythmias or progressively worsening unstable angina;
- Malignancies, lymphoma, leukemia, or other serious conditions associated with a life expectancy of less than 1 year;
- Participation in another investigational drug trial within 4 weeks prior to enrollment or ongoing receipt of any investigational treatment other than the study medication;
- Pregnant or breastfeeding women;
- Known hypersensitivity or allergy to vitamin B preparations;
- Hemodynamic instability;
- Heart failure caused by restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, or primary valvular heart disease;
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07725484, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07725484, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.